Clinical Trials
160 trialsRelugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
DIRECT
University Health Network, Toronto
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
PREDICT
Alliance for Clinical Trials in Oncology
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
MOMENT
Prostate Cancer Clinical Trials Consortium
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
TRAP
Royal Marsden NHS Foundation Trust
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
ENZARAD
University of Sydney
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
University of California, Davis
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
TALENT
Prostate Cancer Clinical Trials Consortium
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
DIVINE
Mayo Clinic
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
University of Chicago
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
University of Oklahoma
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
University of Chicago
ARCH
University of Colorado, Denver
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Beth Israel Deaconess Medical Center
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Alliance for Clinical Trials in Oncology
CASPAR
Alliance for Clinical Trials in Oncology
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
STEEL
RTOG Foundation, Inc.
PROSTEP-002
CHU de Quebec-Universite Laval
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
Institute of Cancer Research, United Kingdom
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Weill Medical College of Cornell University
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Roswell Park Cancer Institute
Testosterone Therapy in Castration Resistant Prostate Cancer
University of Colorado, Denver
ARACOG
Alliance Foundation Trials, LLC.
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins